Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax
TOKUSHIMA, Japan--(BUSINESS WIRE)--Apr 8, 2024--
Stay updated with breaking news from Fly Pharma Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TOKUSHIMA, Japan--(BUSINESS WIRE)--Apr 8, 2024--
TOKUSHIMA, Japan--(BUSINESS WIRE)--Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Ange...
TOKUSHIMA, Japan--(BUSINESS WIRE)--We are excited to share our latest development status.As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive in a...
We are excited to share our latest development status. As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib in stage III/IV non-small cell lung cancer...
TOKUSHIMA, Japan — We are excited to share our latest development status.